Daiichi Sankyo Inc. drugs
5 results
Azor (amlodipine besylate and olmesartan medoxomil)
(amlodipine besylate and olmesartan medoxomil)Daiichi Sankyo Inc.
Usage: Azor is indicated for treating hypertension, either alone or in combination with other antihypertensive agents, to lower blood pressure and reduce the risk of cardiovascular events like strokes and heart attacks. It may also serve as initial therapy for patients likely needing multiple antihypertensive medications.
Datroway (datopotamab deruxtecan)
(Datopotamab Deruxtecan)Daiichi Sankyo Inc.
Usage: DATROWAY is indicated for adult patients with unresectable or metastatic, hormone receptor-positive, HER2-negative breast cancer who have previously undergone endocrine-based therapy and chemotherapy for their condition.
Enhertu (fam-trastuzumab deruxtecan-nxki)
(fam-trastuzumab deruxtecan-nxki)Daiichi Sankyo Inc.
Usage: ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, HER2-low breast cancer, HER2-mutant non-small cell lung cancer, HER2-positive gastric cancer, or HER2-positive solid tumors, following prior systemic treatment or specific therapy regimens.
Savaysa (edoxaban tosylate)
(EDOXABAN TOSYLATE)Daiichi Sankyo Inc.
Usage: SAVAYSA is indicated for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment of deep vein thrombosis and pulmonary embolism after initial parenteral anticoagulant therapy. It should not be used in patients with CrCL > 95 mL/min.
Vanflyta (quizartinib)
(QUIZARTINIB)Daiichi Sankyo Inc.
Usage: VANFLYTA is indicated for adult patients with newly diagnosed FLT3 ITD-positive acute myeloid leukemia (AML) in combination with cytarabine and anthracycline, and as maintenance monotherapy after consolidation chemotherapy. It is not indicated for maintenance following allogeneic hematopoietic stem cell transplantation.